翰宇藥業(300199.SZ):西格列汀二甲雙胍片(Ⅱ)獲批上市並視同通過一致性評價
格隆匯1月13日丨翰宇藥業(300199.SZ)公佈,2023年1月13日,公司收到國家藥品監督管理局下發的《藥品註冊證書》,公司“西格列汀二甲雙胍片(Ⅱ)”獲得藥品註冊批准。
適應症:本品配合飲食和運動治療,用於經二甲雙胍單藥治療血糖仍控制不佳或正在接受二者聯合治療的2型糖尿病患者。
西格列汀二甲雙胍片(Ⅱ)的獲批上市,將進一步豐富公司產品種類,拓展公司的產品佈局。通過一致性評價的產品將具備參加國家藥品集中採購的資格,有利於公司在相應治療領域市場的拓展,提高公司在該治療領域的市場競爭力。本次註冊批件的獲得將對公司未來業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.